Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

Video

Impact of FGFR2/3 Activating Genomic Alterations on Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma (mUC)

Bladder cancer research: Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC) Senior author: Guru Sonpavde, MD ASCO #GU21 Abstract 472

Related Presenters

Guru P. Sonpavde, MD.

Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD was the director of the bladder cancer program at Dana-Farber Cancer Institute and was on the faculty of Harvard Medical School. He completed his medical oncology fellowship at Indiana University. His primary focus ...

View Profile

ADVERTISEMENT

Related Videos